Oncology
Refine Search
Pharmaceutical
The European Commission has approved US pharma major Bristol-Myers Squibb’s Opdivo (nivolumab). 20 June 2015
Biotechnology
A Phase III trial of Vectibix (panitumumab) and best supportive care by USA-based independent biotech firm Amgen met its primary endpoint. 19 June 2015
Biotechnology
The National Institute for Health and Care Excellence (NICE), the medicines watchdog for England and Wales, has opened a consultation on preliminary draft guidance for US biotech giant Gilead Sciences’ Zydelig (idelalisib) for adults with chronic lymphocytic leukemia. 18 June 2015
Biotechnology
The colorectal cancer (CRC) treatment market value will increase at a moderate compound annual growth rate (CAGR) of 1.8%, from $8.3 billion in 2013 to $9.4 billion by 2020, new research finds. 18 June 2015
Pharmaceutical
US pharma major Eli Lilly has entered into a strategic partnership with the Sarah Cannon Research Institute (SCRI) to co-develop an investigational oncology compound, LY3023414, a PI3K/mTOR dual inhibitor. 17 June 2015
Pharmaceutical
Although the pancreatic cancer pipeline is currently highly innovative, a significant proportion of these therapies are unlikely to reach the market in the near future, according to a new report from business intelligence provider GBI Research. 17 June 2015
Pharmaceutical
Northern Ireland-based cancer drug developer Almac Discovery has entered into a research and licensing agreement with Genentech. 17 June 2015
Pharmaceutical
The Abbott government will invest a record A$372 million ($288 million) to ensure Australians continue to have timely access to life-saving chemotherapy drugs, no matter where they live in Australia. 16 June 2015
Pharmaceutical
The global melanoma treatment market value will increase from $1.3 billion in 2013 to $3.6 billion by 2020, at an impressive compound annual growth rate (CAGR) of 15.4%, a new report states. 16 June 2015
Biotechnology
Personalized oncology specialist biopharma company Agalimmune has licensed KODE Biotech’s Function-Spacer-Lipid (FSL) cell surface membrane modification technology. 15 June 2015
Pharmaceutical
Taiho Pharmaceutical and independent French pharma company Servier have entered into an exclusive license agreement for the development and commercialization of TAS-102 (trifluridine and tipiracil hydrochloride) in Europe and other countries. 15 June 2015
Biotechnology
When international pharma companies set up in Switzerland, the question almost immediately becomes “when are you leaving?” once economic incentives become less enticing. Not so for Celgene, which, as of 2015, has spent 10 years with its EMEA headquarters in Boudry, an hour outside Geneva. Tuomo Pätsi, head of Celgene EMEA, was one of three senior members of staff to discuss the company’s anniversary, ethos and goals to 2020 with The Pharma Letter. 11 June 2015
Biotechnology
BIND Therapeuticsand Macrophage Therapeutics, a subsidiary of Navidea Biopharmaceuticals, today announced a research collaboration. 11 June 2015
Biotechnology
San Diego, USA-based biotech firm BioAtla, which is focused on the development of conditionally active biologic (CAB) antibody therapeutics, says that a China-based investor group has purchased $30 million in BioAtla equity. 11 June 2015
Pharmaceutical
The National Institute for Health and Care Excellence (NICE), the medicines watchdog for England and Wales, has published draft guidance in which Japanese drug major Astellas Pharma’s Xtandi (enzalutamide) is not recommended as a drug to treat advanced prostate cancer. 11 June 2015
Pharmaceutical
US drugmaker Ariad Pharmaceuticals has granted Paladin Labs, a unit of Endo International exclusive rights to distribute Iclusig (ponatinib hydrochloride) in Canada for its newly approved indications. 10 June 2015
Pharmaceutical
Privately-held Lycera has entered into an exclusive global collaboration with fellow USA-based biotech firm Celgene Corp to take forward Lycera's proprietary pipeline for cancer and immune-mediated diseases. 9 June 2015
Biotechnology
Seattle Genetics has entered into a strategic collaboration and license agreement with Unum Therapeutics to develop and commercialize novel antibody-coupled T-cell receptor (ACTR) therapies for cancer. 8 June 2015
Pharmaceutical
A partnership has been concluded between Anglo-Swedish pharma major AstraZeneca and the two Algerian companies, Salhi and Hasnaoui, for the production of drugs in Algeria. 8 June 2015
Pharmaceutical
The National Institute for Health and Care Excellence (NICE), the medicines watchdog for England and Wales, has launched public consultations on draft recommendations for two separate prostate cancer drugs. 5 June 2015
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Pharmaceutical
Novartis announced today that the European Commission (EC) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (EBC) at high risk of recurrence. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biosimilars
Samsung Bioepis has appointed Kyung-Ah Kim as its new president and chief executive, succeeding Christopher Hansung Ko, who will lead the Samsung Future Business Division. 27 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Biotechnology
The Phase III SKYSCRAPER-01 trial has missed its primary endpoint, Swiss cancer giant Roche has reported. 26 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for belantamab mafodotin in combinations with bortezomib plus dexamethasone (BorDex [BVd]) and pomalidomide plus dexamethasone (PomDex [BPd]) for multiple myeloma patients who have received at least one prior line of therapy. 25 November 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Imkeldi (imatinib) oral solution, the first oral liquid form of imatinib to treat certain forms of leukemia and other cancers, from privately-held US-Ireland-based pharmaceutical company Shorla Oncology. 25 November 2024
Biotechnology
Danish biotech Adcendo today announced the successful closing of an oversubscribed $135 million Series B financing round. 25 November 2024
Generics
Sino-American oncology company BeOne Medicines, until now known as BeiGene, has entered into a settlement agreement with MSN Pharmaceuticals and MSN Laboratories Private resolving patent litigation related to MSN’s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Brukinsa (zanubrutinib) in the USA. 25 November 2024
Pharmaceutical
UK pharma major AstraZeneca today released positive high-level results from the CAPItello-281 Phase III trial showing that its Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT). 25 November 2024
Biotechnology
Research news last week included US biotech releasing early data for its FT819 in the treatment of systemic lupus erythematosus (SLE), which sent the firm’s shares leaping as much as 70%. Also, Netherlands-based NewAmsterdam Pharma announced positive data on its obicetrapib and ezetimibe combination in cardiovascular disease. On the regulatory front, Dutch firm argenX and China’s Zai Lab gained approval from the Chinese medicines regulator for their Vyvgart Hytrulo in chronic inflammatory demyelinating polyneuropathy (CIDP) care. Meantime, USA-based Kura Oncology signed a collaboration with Japan’s Kyowa Kirin on the development of ziftomenib for myeloid leukemia (ALS). 24 November 2024
Pharmaceutical
Japanese mid-size drugmaker Otsuka Pharmaceutical announced that it has entered into an exclusive worldwide licensing agreement with Ionis Pharmaceuticals for rights to manufacture and market Ionis' ulefnersen (ION363), a drug candidate under development for the treatment of patients with amyotrophic lateral sclerosis (ALS) caused by mutation of the fused in sarcoma (FUS) gene. 23 November 2024
Biotechnology
Japanese drugmaker Takeda has launched Fruzaqla (fruquintinib) in its home country. 22 November 2024
Biotechnology
Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Biotechnology
Privately-held US biotech Alloy Therapeutics has announced a strategic collaboration and license agreement with Takeda Pharmaceutical. 21 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze